CyPath Lung Q2 results
CyPath Lung test volume increased 216% year over year, boosting H1 2026 revenue to $835,000 and bolstering the company's commercial momentum. Bottom-line financials are currently unavailable.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day